Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Merck & Co., Inc.. A complete text table follows the diagram.
Keytruda crossed $8 billion and Winrevair accelerated, but the upfront accounting charge for Cidara's influenza candidate overwhelmed current-period earnings
Swipe to explore
All values are directly reported or exact arithmetic sums. Because a nonnegative Sankey cannot subtract expenses into a loss, the visualization contains two factual components: the sales portfolio and a pretax bridge in which $15.881 billion of net unallocated charges split between $12.347 billion of business contribution absorbed and the reported $3.534 billion pretax loss.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Keytruda & Keytruda Qlex | 1 | $8.0B | 49% of company sales; up 12% |
| Other pharmaceuticals & vaccines | 1 | $6.3B | Oncology, vaccines and cardiometabolic portfolio |
| Animal Health | 1 | $1.8B | Livestock and companion-animal medicines |
| Corporate & other sales | 1 | $146M | Milestones, manufacturing and hedging |
| Total sales | 2 | $16.3B | Up 5% year over year |
| Net unallocated charges | 3 | $15.9B | R&D, acquisition charges, amortization and corporate costs |
| Business contribution absorbed | 4 | $12.3B | Segment profits plus other profits |
| Loss before taxes | 4 | $3.5B | After acquisition-led R&D spending |
| Income tax provision | 4 | $709M | Tax expense despite pretax loss |
| Net loss | 5 | $4.2B | Versus $5.085B profit one year earlier |
| From | To | Value |
|---|---|---|
| Keytruda & Keytruda Qlex | Total sales | $8.0B |
| Other pharmaceuticals & vaccines | Total sales | $6.3B |
| Animal Health | Total sales | $1.8B |
| Corporate & other sales | Total sales | $146M |
| Net unallocated charges | Business contribution absorbed | $12.3B |
| Net unallocated charges | Loss before taxes | $3.5B |
| Loss before taxes | Net loss | $3.5B |
| Income tax provision | Net loss | $709M |